Pierre L. Triozzi

5.1k total citations · 1 hit paper
152 papers, 3.9k citations indexed

About

Pierre L. Triozzi is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Pierre L. Triozzi has authored 152 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 74 papers in Immunology and 44 papers in Molecular Biology. Recurrent topics in Pierre L. Triozzi's work include Immunotherapy and Immune Responses (59 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Ocular Oncology and Treatments (23 papers). Pierre L. Triozzi is often cited by papers focused on Immunotherapy and Immune Responses (59 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Ocular Oncology and Treatments (23 papers). Pierre L. Triozzi collaborates with scholars based in United States, India and Austria. Pierre L. Triozzi's co-authors include Wayne Aldrich, Arun D. Singh, Laura F. Hutchins, Dorit Elisabeth Schuller, Stephen K. Williamson, Julie A. Kish, Barbara Metch, John F. Ensley, Stephanie E. McClure and Arlene A. Forastiere and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Pierre L. Triozzi

147 papers receiving 3.8k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

1992 550 citations Pierre L. Triozzi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pierre L. Triozzi United States	33	1.8k	1.4k	1.3k	705	502	152	3.9k
Ekaterina S. Jordanova Netherlands	49	3.4k 1.9×	1.6k 1.1×	3.5k 2.6×	565 0.8×	681 1.4×	156	7.2k
Nicole Basset‐Séguin France	41	2.0k 1.1×	2.5k 1.8×	496 0.4×	1.2k 1.7×	244 0.5×	189	6.5k
Lorenzo Leoncini Italy	40	2.7k 1.5×	1.7k 1.3×	922 0.7×	439 0.6×	109 0.2×	221	5.6k
José Luis Rodríguez‐Peralto Spain	35	1.5k 0.8×	1.4k 1.0×	474 0.4×	868 1.2×	78 0.2×	316	4.8k
Mauro Truini Italy	27	948 0.5×	677 0.5×	825 0.6×	468 0.7×	161 0.3×	101	2.6k
Thomas Löning Germany	44	2.2k 1.2×	1.6k 1.2×	694 0.5×	396 0.6×	26 0.1×	137	5.4k
Sara I. Pai United States	41	2.8k 1.6×	2.0k 1.4×	2.1k 1.6×	767 1.1×	32 0.1×	141	7.5k
Miguel N. Burnier Canada	30	1.0k 0.6×	1.0k 0.7×	611 0.5×	386 0.5×	2.1k 4.2×	317	4.0k
Willem Den Otter Netherlands	31	946 0.5×	822 0.6×	1.3k 1.0×	440 0.6×	358 0.7×	193	3.6k
Gunnar Kvalheim Norway	43	2.9k 1.6×	1.7k 1.2×	1.8k 1.4×	571 0.8×	66 0.1×	173	5.5k

Countries citing papers authored by Pierre L. Triozzi

Since Specialization

Citations

This map shows the geographic impact of Pierre L. Triozzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre L. Triozzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre L. Triozzi more than expected).

Fields of papers citing papers by Pierre L. Triozzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre L. Triozzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre L. Triozzi. The network helps show where Pierre L. Triozzi may publish in the future.

Co-authorship network of co-authors of Pierre L. Triozzi

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre L. Triozzi. A scholar is included among the top collaborators of Pierre L. Triozzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre L. Triozzi. Pierre L. Triozzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bitting, Rhonda L., Janet A. Tooze, Michael Goodman, et al.. (2024). Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma. Cancer Research Communications. 4(2). 530–539. 3 indexed citations

Song, Alexander H., Thomas Lycan, Rebecca L. Kinney, et al.. (2024). Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer. Therapeutic Advances in Medical Oncology. 16. 2662695–2662695. 1 indexed citations

Votanopoulos, Konstantinos I., Steven D. Forsythe, Hemamylammal Sivakumar, et al.. (2019). Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study. Annals of Surgical Oncology. 27(6). 1956–1967. 127 indexed citations

Thomas, Alexandra, Eric D. Routh, Ashok Pullikuth, et al.. (2018). Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. OncoImmunology. 7(10). e1490854–e1490854. 209 indexed citations

Porosnicu, Mercedes, Joshua D. Waltonen, & Pierre L. Triozzi. (2018). Anti-tumor Effect of PD-L1 Inhibitor Durvalumab Administered Before Surgery in Patients With HPV+ vs HPV- HNSCC. International Journal of Radiation Oncology*Biology*Physics. 100(5). 1316–1316. 3 indexed citations

Crabb, John W., John S. Crabb, Bo Hu, et al.. (2015). iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors. PLoS ONE. 10(8). e0135543–e0135543. 26 indexed citations

Negrotto, Soledad, Zhenbo Hu, Óscar Garnica, et al.. (2011). Noncytotoxic Differentiation Treatment of Renal Cell Cancer. Cancer Research. 71(4). 1431–1441. 23 indexed citations

Borden, Ernest C., Barbara Jacobs, Lisa Rybicki, et al.. (2011). Gene Regulatory and Clinical Effects of Interferon β in Patients with Metastatic Melanoma: A Phase II Trial. Journal of Interferon & Cytokine Research. 31(5). 433–440. 25 indexed citations

Triozzi, Pierre L., Jatin J. Shah, Wayne Aldrich, et al.. (2006). Anti-GD3 Monoclonal Antibody Effects on Lymphocytes and Antibody-Dependent Cellular Cytotoxicity. Cancer Biotherapy and Radiopharmaceuticals. 21(6). 553–560. 5 indexed citations

10.

Forero, Andres, et al.. (2006). A Phase I Study of an Anti-GD3 Monoclonal Antibody, KW-2871, in Patients with Metastatic Melanoma. Cancer Biotherapy and Radiopharmaceuticals. 21(6). 561–568. 20 indexed citations

11.

Triozzi, Pierre L., Julian Kim, & Wayne Aldrich. (2003). Infusion of Unpulsed Dendritic Cells Derived from Granulocyte/Macrophage Colony-Stimulating Factor-Mobilized Peripheral Blood CD34 ⁺ Cells and Monocytes in Patients with Advanced Carcinoma. Journal of Hematotherapy & Stem Cell Research. 12(3). 279–287. 4 indexed citations

12.

Dakappagari, Naveen, et al.. (2000). Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.. PubMed. 60(14). 3782–9. 96 indexed citations

13.

Kim, Julian A., et al.. (1999). Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody. Cancer. 86(1). 22–30. 2 indexed citations

14.

Blakeslee, James R., et al.. (1998). Adoptive Immunotherapy of Feline Leukemia Virus Infection Using Autologous Lymph Node Lymphocytes. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 18(1). 1–6. 9 indexed citations

15.

Triozzi, Pierre L., et al.. (1997). Clinical and Immunologic Effects of Monoclonal Antibody CC49 and Interleukin-2 in Patients with Metastatic Colorectal Cancer. Hybridoma. 16(2). 147–151. 3 indexed citations

16.

Triozzi, Pierre L., G D Stoner, & Pravin T. P. Kaumaya. (1995). Subunit peptide cancer vaccines targeting activating mutations of the p21 ras proto-oncogene.. PubMed. 1(3). 185–92. 2 indexed citations

17.

Snyder, Laura L., David Woo, Pierre L. Triozzi, & Vernon C. Stevens. (1995). Synthetic Hormone/Growth Factor Subunit Vaccine with Application to Antifertility and Cancer. Pharmaceutical biotechnology. 6. 907–930. 5 indexed citations

18.

Rinehart, J. J., Kim Margolin, Pierre L. Triozzi, et al.. (1995). Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.. PubMed. 1(10). 1139–44. 3 indexed citations

19.

Triozzi, Pierre L., et al.. (1994). Localization of tumor-reactive lymph node lymphocytes in vivo using radiolabeled monoclonal antibody. Cancer. 73(3). 580–589. 25 indexed citations

20.

Kinney, Patrick L., et al.. (1990). Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.. Journal of Clinical Oncology. 8(5). 881–885. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact